Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? the HIV-TB pharmagene study

Pharmacogenomics

Volumn 16, Issue 10, 2015, Pages 1047-1064

  Habtewold, Abiy ^a,b   Makonnen, Eyasu ^b   Amogne, Wondwossen ^b,c   Yimer, Getnet ^a,b   Aderaye, Getachew ^b   Bertilsson, Leif ^a   Burhenne, Jurgen ^d   Aklillu, Eleni ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CYP2B6 efavirenz; Ethiopia; HIV AIDS; rifampicin; sub Saharan Africa; treatment guideline; tuberculosis

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; ETHAMBUTOL; GENOMIC DNA; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT;

ADULT; AFRICA SOUTH OF THE SAHARA; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; CLINICAL TRIAL; COINFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; METABOLISM; MULTICENTER STUDY; PHARMACOGENETICS; PROCEDURES;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; COINFECTION; CYTOCHROME P-450 CYP2B6; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; PHARMACOGENETICS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TUBERCULOSIS;

EID: 84941616954     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.35     Document Type: Article

References (44)

1. Semvua HH, Kibiki GS. AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus. BMC Res. Notes 4, 511 (2011).
2. Yimer G, Ueda N, Habtewold A et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE 6(12), e27810 (2011).
3. Mugusi S, Ngaimisi E, Janabi M et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis coinfection in Tanzania. PLoS ONE 7(7), e40180 (2012).
4. Habtewold A, Amogne W, Makonnen E et al. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J. 13(6), 484-489 (2013).
5. Habtewold A, Amogne W, Makonnen E et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J. Antimicrob. Chemother. 66(10), 2350-2361 (2011).
6. Ngaimisi E, Mugusi S, Minzi O et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin. Pharmacol. Ther. 90(3), 406-413 (2011).
7. Ngaimisi E, Mugusi S, Minzi OM et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin. Pharmacol. Ther. 88(5), 676-684 (2010).
8. Best BM, Goicoechea M. Efavirenz-still first-line king? Expert Opin. Drug Metab. Toxicol. 4(7), 965-972 (2008).
9. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J. Antimicrob. Chemother. 64(5), 910-928 (2009).
10. Manosuthi W, Kiertiburanakul S, Sungkanuparph S et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 20(1), 131-132 (2006).
11. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin. Pharmacokinet. 41(9), 681-690 (2002).
12. Yenny Nafrialdi, Djoerban Z et al. Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 49(2), 162-168 (2011).
13. Rekic D, Roshammar D, Mukonzo J et al. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br. J. Clin. Pharmacol. 71(4), 536-543 (2011).
14. Mukonzo JK, Okwera A, Nakasujja N et al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect. Dis. 13, 261 (2013).
15. Cohen K, Grant A, Dandara C et al. Effect of rifampicinbased antitubercular therapy and the cytochrome P450 2B6 516 G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir. Ther. 14(5), 687-695 (2009).
16. Ren Y, Nuttall JJ, Eley BS et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J. Acquir. Immune Defic. Syndr. 50(5), 439-443 (2009).
17. Gengiah TN, Holford NH, Botha JH et al. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur. J. Clin. Pharmacol. 68(5), 689-695 (2012).
18. Kwara A, Lartey M, Sagoe KW et al. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampincontaining antituberculous therapy. AIDS 25(3), 388-390 (2011).
19. Rosenkranz SL, Lu D, Marzan F et al. Relationship between weight, efavirenz exposure and virologic suppression in HIV-infected patients on rifampin-based TB treatment in the ACTG A5221 STRIDE study. Clin. Infect. Dis. (2013).
20. Orrell C, Cohen K, Conradie F et al. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir. Ther. 16(4), 527-534 (2011).
21. Ngaimisi E, Habtewold A, Minzi O et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallelgroup prospective cohort study in two sub-Saharan Africa populations. PLoS ONE 8(7), e67946 (2013).
22. Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308(4), 387-402 (2012).
23. U. S. Food and Drug administration. Sustiva labeling update/dosing adjustment with rifampin. http://archive. today/Qqaq6
24. Pozniak AL, Coyne KM, Miller RF et al. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med. 12(9), 517-524 (2011).
25. Lopez-Cortes LF, Ruiz-Valderas R, Marin-Niebla A et al. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J. Acquir. Immune Defic. Syndr. 39(5), 551-556 (2005).
26. Burhenne J, Matthee AK, Pasakova I et al. No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob. Agents Chemother. 54(10), 4185-4191 (2010).
27. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use ofantiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo. nih. gov/contentfiles/lvguidelines
28. Yimer G, Amogne W, Habtewold A et al. High plasma efavirenz level and CYP2B6∗6 are associated with efavirenzbased HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J. 12(6), 499-506 (2012).
29. Mukonzo JK, Nanzigu S, Rekic D et al. HIV/AIDS Patients display lower relative bioavailability of efavirenz than healthy subjects. Clin. Pharmacokinet. 50(8), 531-540 (2011).
30. Mukonzo JK, Nanzigu S, Waako P et al. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Pharmacogenomics 15(11), 1423-1435 (2014).
31. Friedland G, Khoo S, Jack C et al. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. Antimicrob. Chemother. 58(6), 1299-1302 (2006).
32. Mcilleron HM, Schomaker M, Ren Y et al. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS 27(12), 1933-1940 (2013).
33. Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin. Drug Metab. Toxicol. 6(1), 55-68 (2010).
34. Ramachandran G, Hemanth Kumar AK, Rajasekaran S et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob. Agents Chemother. 53(3), 863-868 (2009).
35. Manosuthi W, Sukasem C, Lueangniyomkul A et al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob. Agents Chemother. 57(2), 1019-1024 (2013).
36. Group ES, Puls R, Amin J et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviralnaive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383(9927), 1474-1482 (2014).
37. Mukonzo JK, Owen JS, Ogwal-Okeng J et al. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS ONE 9(1), e86919 (2014).
38. Ogburn ET, Jones DR, Masters AR et al. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38(7), 1218-1229 (2010).
39. Court MH, Almutairi FE, Greenblatt DJ et al. Isoniazid mediates the CYP2B6∗6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6. Antimicrob. Agents Chemother. 58(7), 4145-4152 (2014).
40. Wen X, Wang JS, Neuvonen PJ et al. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 57(11), 799-804 (2002).
41. Wanchu A, Kuttiatt VS, Sharma A et al. CD4 cell count recovery in HIV/TB co-infected patients versus TB uninfected HIV patients. Indian J. Pathol. Microbiol. 53(4), 745-749 (2010).
42. Yimer G, Gry M, Amogne W et al. Evaluation of patterns of liver toxicity in patients on antiretroviral and antituberculosis drugs: a prospective four arm observational study in ethiopian patients. PLoS ONE 9(4), e94271 (2014).
43. Mukonzo J, Roshammar D, Waako P et al. A novel polymorphism in ABCB1 gene, CYP2B6∗6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br. J. Clin. Pharmacol. 68(5), 690-699 (2009).
44. Aklillu E, Dandara C, Bertilsson L et al. Pharmacogenetics of cytochrome P450s in African populations: clinical and molecular evolutionary implications. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed. ). Landes Bioscience, TX, USA, 99-119 (2007).